Pregabalin for Treatment of Generalized Anxiety Disorder

Rickels, Karl; Pollack, Mark H.; Feltner, Douglas E.; Lydiard, R. Bruce; Zimbroff, Daniel L.; Bielski, Robert J.; Tobias, Kathy; Brock, Jerri; Zornberg, Gwen L.; Pande, Atul C.

doi:10.1001/archpsyc.62.9.1022

Cited by 246 publications

(27 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pregabalin: The anticonvulsant pregabalin was more effective than placebo in RCTs [576,577,592,593,597,613] and as effective as benzodiazepines [592,593,597] in patients with GAD (Level 1). Pregabalin was more effective than venlafaxine XR in one RCT [577], but equivalent in another [576].…”

Section: Generalized Anxiety Disordermentioning

confidence: 99%

Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders

et al. 2014

View full text Add to dashboard Cite

BackgroundAnxiety and related disorders are among the most common mental disorders, with lifetime prevalence reportedly as high as 31%. Unfortunately, anxiety disorders are under-diagnosed and under-treated.MethodsThese guidelines were developed by Canadian experts in anxiety and related disorders through a consensus process. Data on the epidemiology, diagnosis, and treatment (psychological and pharmacological) were obtained through MEDLINE, PsycINFO, and manual searches (1980–2012). Treatment strategies were rated on strength of evidence, and a clinical recommendation for each intervention was made, based on global impression of efficacy, effectiveness, and side effects, using a modified version of the periodic health examination guidelines.ResultsThese guidelines are presented in 10 sections, including an introduction, principles of diagnosis and management, six sections (Sections 3 through 8) on the specific anxiety-related disorders (panic disorder, agoraphobia, specific phobia, social anxiety disorder, generalized anxiety disorder, obsessive-compulsive disorder, and posttraumatic stress disorder), and two additional sections on special populations (children/adolescents, pregnant/lactating women, and the elderly) and clinical issues in patients with comorbid conditions.ConclusionsAnxiety and related disorders are very common in clinical practice, and frequently comorbid with other psychiatric and medical conditions. Optimal management requires a good understanding of the efficacy and side effect profiles of pharmacological and psychological treatments.

show abstract

Section: Generalized Anxiety Disordermentioning

confidence: 99%

Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders

et al. 2014

View full text Add to dashboard Cite

show abstract

“…A meta-analysis in patient with GAD showed equal efficacy between pregabalin and the other comparators studied: duloxetine, ecitalopram, paroxetine, and venlafaxine (69). Pregabaline was also similarly effective in GAD compared to alprazolam and lorazepam (70, 71). There is limited evidence showing the efficacy of pregabalin augmentation with SSRI in OCD or PTSD (72, 73).…”

Section: Competitive Environmentmentioning

confidence: 96%

“…Pregabalin has demonstrated efficacy in several RCTs in GAD (67, 68), although the FDA ultimately determined that there was insufficient evidence of efficacy to grant approval. A meta-analysis in patient with GAD showed equal efficacy between pregabalin and the other comparators studied: duloxetine, ecitalopram, paroxetine, and venlafaxine (69).…”

Section: Competitive Environmentmentioning

confidence: 99%

Emerging drugs for the treatment of anxiety

Murrough

Yaqubi

Sayed

et al. 2015

Expert Opinion on Emerging Drugs

131

View full text Add to dashboard Cite

Introduction Anxiety disorders are among the most prevalent and disabling psychiatric disorders in the United States and worldwide. Basic research has provided critical insights into the mechanism regulating fear behavior in animals and a host of animal models have been developed in order to screen compounds for anxiolytic properties. Despite this progress, no mechanistically novel agents for the treatment of anxiety have come to market in more than two decades. Areas covered The current review will provide a critical summary of current pharmacological approaches to the treatment of anxiety and will examine the pharmacotherapeutic pipeline for treatments in development. Anxiety and related disorders considered herein include panic disorder, social anxiety disorder, generalized anxiety disorder and posttraumatic stress disorder. The glutamate, neuropeptide and endocannabinoid systems show particular promise as future targets for novel drug development. Expert opinion In the face of an ever-growing understanding of fear related behavior, the field awaits the translation of this research into mechanistically novel treatments. Obstacles will be overcome through close collaboration between basic and clinical researchers with the goal of aligning valid endophenotypes of human anxiety disorders with improved animal models. Novel approaches are needed to move basic discoveries into new, more effective treatments for our patients.

show abstract

“…Treatments that more fully address the full spectrum of CNS disorders should lead to more optimal patient outcomes. Pregabalin, an ␣2-␦ modulator, has been shown to be effective and well tolerated for the treatment of peripheral neuropathic pain [1,2], as add-on treatment of partial seizures [3], for generalised anxiety disorder [4], and for central pain following spinal cord injury [5]. Consistently through these trials, pregabalin has been associated with a significant improvement in measures of sleep disturbance associated with these CNS disorders.…”

Section: Heidelberg Germanymentioning

confidence: 99%

Satellite Symposia

2006

Euro J of Neurology

View full text Add to dashboard Cite

Pregabalin for Treatment of Generalized Anxiety Disorder

Abstract: Pregabalin was significantly more efficacious than placebo for the treatment of psychic and somatic symptoms of generalized anxiety disorder and was well tolerated by most study patients.

Cited by 246 publications

References 38 publications

Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders

Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders

Emerging drugs for the treatment of anxiety

Satellite Symposia

Contact Info

Product

Resources

About